INTRODUCTION
Ras proteins are small GTPases that regulate the flow of mitogenic signals from cell surface receptors to the internal cell signaling machinery (1,2) To achieve this, Ras proteins shuttle between an active, GTP-bound form and an inactive GDP-bound form under the influence of Guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) (3, 4, 5) Activated Ras proteins induce a wide variety of biological phenotypes associated with the loss of normal growth control. These include loss of contact inhibition (6), resistance to differentiation (7, 8) , disruption of cytoskeletal architecture (9) , reduced requirement for growth factors (10) , enhanced invasiveness (11, 12) resistance to apoptosis (13) and tumorigenic transformation (1, 14) .
However, activated Ras may also induce senescence (15) , differentiation (16) , cell cycle arrest (17) or apoptosis (18, 19) . Thus, paradoxically, Ras can either drive processes that are normally associated with the acquisition of a transformed phenotype, or processes that promote growth arrest and death. The normal role of Ras in vivo must involve a fine balance of these properties (20) . The ability of Ras to produce such a range of apparently contradictory biological effects may be derived from its ability to interact with a diverse array of effector proteins (2) . Although effectors mediating the positive growth effects of Ras have been relatively well characterized, the effectors mediating the negative growth aspects remain relatively poorly defined.
Recently, we demonstrated that the tumor suppressor RASSF1 (21) has the potential to serve as a Ras effector mediating Ras dependent apoptosis (22) . At the time we speculated that Nore1, which bears considerable resemblance to RASSF1 (Figure 1 ), might also be a Ras regulated tumor suppressor. Khokhlatchev et al (23) have now shown that Nore1 can induce apoptosis and Tommasi et al (24) have shown that some forms of the Nore1 mRNA are down regulated in a lung tumor cell line. We now show that Nore1 mediated apoptosis is Ras dependent. Moreover, using a polyclonal antibody, we show that Nore1 protein expression is frequently down-regulated, both in human lung tumor cell lines and in primary tumors. Although Tommasi et al (24) were unable to determine a mechanism for the down regulation, we have found evidence of epigenetic inactivation of Nore1 by promotor methylation. Furthermore, by reintroducing Nore1 under the control of its own promoter, we were able to impair the ability of a human lung tumor cell line to grow in soft agar. Consequently, we propose that, like RASSF1, Nore1 may function as a Ras regulated tumor suppressor.
EXPERIMENTAL PROCEDURES

Cloning of Nore1/Maxp1
The Rat ortholog of Nore1 (Maxp1) was identified by a tBlastn search of the Genbank database using the amino acid sequence of murine Nore1 as the query. Maxp1 shows over 94% identity to Nore1. The Maxp1 coding sequence was isolated by PCR from a Rat brain cDNA library, using the following primers to introduce convenient restriction sites (BglII/EcoR1) at the 5'and 3' ends:
(ggggagatctatggcgtccccggccattg), (ggggaattccttacccaggcttcccttgg). We have confirmed that the Rat Maxp1 protein binds Ras in a GTP dependent manner (data not shown). To reduce confusion, we will subsequently refer to this protein as Nore1. The Nore1 gene was cloned as a BglII/EcoR1 fragment into the BamH1/EcoR1 sites of pcDNAF, a modified version of pcDNA3 (Invitrogen, Carlsbad CA) which adds a FLAG epitope tag to the insert. Nore1 was also cloned via the BamH1/EcoRI sites into pZIP-NeoHA, a modified version of pZIPNeo SV(X)1 (25) , which adds a Haemagluttinin epitope tag to the inserted gene. The immediate 1.6 Kb 5' promoter region was amplified from the human Nore1BAC clone (Genbank AL354681.2) by PCR using the primers (ggtaccggcagaggactatgattaccgtga) and (ctcgaggggtccaatagtagcgggtacg). These primers introduce a KpnI and an XhoI restriction sirte at the 5' and 3' end respectively (shown underlined). After sequence confirmation, the 1.6 Kb promoter fragment was cloned into the KpnI/XhoI sites in the vector pGL3-Luc (Promega, Palo Alto CA). The luciferase gene was then excised from this vector and replaced with a full length BglII/SalI fragment of Nore1. For fluorescent analyses Nore1 was cloned into the BglII/EcoR1 sitesof the pHcRedC vector (Clontech, Palo Alto, CA).
Cell culture and transfections. NIH 3T3 cells were grown in 10% Calf serum and DMEM.
293-T and 293 cells were grown in DMEM and 10% FBS. Human lung tumor cells were grown in RPMI with 10% FBS. NIH 3T3 and 293-T cells were transfected using the calcium phosphate technique (26) . Cell selection experiments were performed using pZIPNeoHA vectors, with the cells selected in medium supplemented with 0.5 mg/ml G418 for 2 weeks. Cells were then fixed and stained in 10% methanol, 10% acetic acid and 0.5% crystal violet before counting. Soft agar assays were performed as described previously (27) . Human lung tumor cell lines were obtained from the ATCC (Manassas, VA). A549 cells were co-transfected with 500 ng of pGL3(-Luc/+Nore1) plasmid and 50 ng of pBabe- Demethylating assays-assays were performed by incubating the cells in growth medium supplemented with 5-10 µM Aza-cytidine (Sigma, St.Louis, MS) for 4 days. Cells were then lysed and examined for re-expression of Nore1 by western blot analysis.
Deacetylation assays-Cells were treated with 250 nM Trichostatin A (Sigma, St. Louis MS) for 48/72 hours before being subjected to Western analysis using Nore1 anti-sera. Nore1 mRNA is widely expressed in human tissue. To examine the expression of Nore1 mRNA in normal human tissue, we performed Northern analysis using a 450 bp fragment of the human cDNA as a probe. Nore1 was expressed in all tissue to some extent but was most evident in lung, spleen, thymus and peripheral blood samples ( Figure   6 ).
RESULTS
Alignment of Nore1 and RASSF1-
Expression of Nore1 protein is frequently lost in human lung tumor cell lines.
In order to examine endogenous Nore1 at a protein level, we generated a Nore1 specific polyclonal antibody (see methods). The antibody can recognize both splice variants 1A and 1B (31) . Protein lysates from a series of human lung tumor cell lines, and one nontransformed lung epithelial cell line (HBEC), were quantitated and equal protein concentrations subjected to Western analysis for Nore1 (Figure 7) . Expression of PCNA (proliferating cell nuclear antigen) was used as an internal control for protein loading. To determine if Nore1 is deleted in Nore1 negative tumor cell lines we digested high molecular weight DNA with BamH1 and subjected to Southern analysis using the Nore1 cDNA as a probe. An internal BamH1 fragment was present in all cell lines tested (Figure 9a ). Therefore, we failed to detect any obvious loss of the Nore1 gene.
To determine if the silencing of Nore1 expression in A549 and H345 cells might be due to promoter methylation, we examined the methylation status of a CpG island just upstream of the initiation codon of Nore1A. This region contains a methylation sensitive restriction site for HaeII. DNA was digested with HaeII and subjected to Southern analysis using a probe consisting of the 1.6 kb promoter region immediately upstream of the Nore1A initiation codon (residues 69241-72957 of Genbank version AL354681.2).
Digestion of the HaeII site is predicted to release a 3.7 kb fragment that should hybridize with the probe. The 3.7 kb band was detected in the N417 and H82 cell lanes (positive for Nore1 expression) but not in the A549 or H345 cell lanes (negative for Nore1 expression) (Figure 9b.) To confirm that epigenetic effects were responsible for the loss of Nore1 expression in lung tumor cells lines, we treated the A549 human lung tumor cell line with the demethylating agent 5-azacytidine (5-AzaC). We also treated the cells with a deacetylating agent, Trichostatin A. We then examined the effects of drug treatment on Nore1 protein expression by Western blot. 5-AzaC caused an increase in Nore1 expression ( Figure 10 ). Trichostatin A had no effect on Nore1 expression, although it did activate p21 ( Figure 11 ) . Thus, promoter silencing by methylation rather than acetylation or gene deletion is the likely mechanism behind the down-regulation of Nore1 expression in lung tumor cells.
Introduction of Nore1 into human lung tumor cells impairs their ability to proliferate
in soft agar. A549 human lung carcinoma cells are negative for the expression of Nore1 (see Figure 7) . Introduction of Nore1 driven by a retroviral promoter inevitably resulted in cell death. Moreover, repeated attempts to generate Nore1 inducible cell systems failed due to cell death, even in the absence of induction (data not shown).
Consequently, in order to determine the effects of re-introducing Nore1 to A549 cells, we cloned the Nore1 promoter from the BAC clone into pGL3Luc (Promega, Palo Alto, CA). We then replaced the luciferase gene with our Nore1 cDNA. This construct, with the Nore1 cDNA under the transcriptional control of it's own promoter, was then co-transfected into A549 cells in molar excess with the selectable vector pBabe (25) . (20) . Ras is not alone in this capacity, as a similar dual role has been described for the oncoprotein myc (36) . It seems that pathways promoting proliferation and those promoting death are coupled and that this linkage may play an important part in checking the development of neoplasia.
The ability of activated Ras to induce senescence, necrosis, cell cycle arrest, differentiation or apoptosis is well documented (15, 18, 38, 39, 40) . However, the mechanisms underlying these effects of Ras remain but poorly understood. Although excessive activation of the Raf/MAP kinase pathway can cause growth inhibition and death (39) , it is unclear that such hyper-activation can occur under physiological conditions. It seems likely that Ras may also be able to stimulate other inhibitory pathways. One may imagine that subversion of the Ras pathways leading to cell death must be a critical component of the development of a Ras dependent tumor. RASSF1 has several related family members described in the EST database. One such protein is the Ras effector Nore1. Consequently, we were interested in determining if Nore1 also exhibited the properties of a tumor suppressor that can be activated by Ras.
We found that cell lines cannot tolerate the deregulated expression of Nore1.
Even non-transformed cells that still produce endogenous protein are affected. This may be due to a dosage effect or perhaps due to the inability to regulate Nore1 levels over the Interestingly, although the Nore1 related RASSF1 gene is located on a region of the chromosome which often suffers deletions, it appears that RASSF1 is not usually itself the subject of deletion. Instead, down-regulation frequently occurs by promoter methylation (32) . To examine the possibility that Nore1 was being down-regulated by promoter methylation, we examined an area of the promoter of Nore1A just upstream of the start codon in a predicted CpG island. By restriction digestion with a methylation sensitive enzyme, we found enhanced DNA methylation of the Nore1A promoter in A549 cells. Moreover, partial restoration of Nore1 protein expression could be obtained by treating the cells with a demethylating agent. Thus Nore1 and RASSF1 seem to share a common mechanism of down regulation. Tommasi et al (24) examined numerous tumor cell lines and were unable to detect Nore1B promoter methylation by PCR of bisulphate treated DNA. They stated that a similar result was obtained with the Nore1A promoter, but this was described as data not shown. At present, it is unclear to us why our results disagree, other than the possibility that our experimental approach was more direct.
Finally, we attempted to reintroduce Nore1 expression in a Nore1 negative cell line to determine if we could see a reduction of the transformed phenotype of the cells.
Initially we used a series of inducible vector systems. In each case, the Nore1 inducible vector proved to be highly growth inhibitory, even without induction (using pIND 
